Journal of Medicinal Chemistry

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Genentech, Peripheral neuropathy, Journal, Private Securities Litigation Reform Act, Phase, Therapy, Neck, Medicinal chemistry, CD137, Biotechnology, MT1-MMP, BTC, Incidence, U.S. Securities and Exchange Commission, Toxic leukoencephalopathy, Journal of Medicinal Chemistry, COVID-19, Esophageal cancer, Ovary, Head, Research, Molecular Cancer Research, Rash, Clinical trial, Cancer research, Forward-looking statement, Cancer, NASDAQ, American Association for Cancer Research, Non-small-cell lung carcinoma, Drug development, Risk, Program, Technology, Security (finance), Thromboxane A2, SEC, Treatment, Patient, Triple-negative breast cancer, Pharmaceutical industry, Bicycle

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.
  • We are encouraged by the continued clinical progress across our pipeline, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • In September, Bicycle announced top-line results from the Phase I dose escalation portion of its Phase I/II trial of BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2, in patients with advanced solid tumors.
  • In June 2022, Bicycle announced the dosing of the first patient in the Phase II dose expansion portion of the Phase I/II trial.

KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat

Retrieved on: 
Wednesday, October 19, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, U.S. Securities and Exchange Commission, DME, Acid dissociation constant, American Chemical Society, Tmax, Protease, NASDAQ, HAE, Security (finance), Annual report, Plasma kallikrein, Private Securities Litigation Reform Act, Form 10-K, Diabetic retinopathy, Hereditary angioedema, Absorption, Journal of Medicinal Chemistry, Safety, American, Journal, Plasma, Medicinal chemistry, Forward-looking statement, Metabolism, FDA, COVID-19, Risk, Xenobiotic, Toxicology, KALV, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica.
  • The Journal of Medicinal Chemistry article focuses on the medicinal chemistry KalVista conducted that led to the discovery of sebetralstat, with properties optimized for the on-demand treatment of hereditary angioedema (HAE).
  • These foundational papers further demonstrate the promise of sebetralstat for the on-demand treatment of HAE attacks, said Andrew Crockett, Chief Executive Officer of KalVista.
  • Additional details can be found in the manuscripts, which are available at:
    The Journal of Medicinal Chemistry is a biweekly peer-reviewed medical journal published by the American Chemical Society covering research in medicinal chemistry.

Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program

Retrieved on: 
Monday, October 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, U.S. Securities and Exchange Commission, American Association for Cancer Research, Molecular Cancer Research, Therapy, Risk, SEC, Bicycle, NASDAQ, Neoplasm, Drug development, Biotechnology, CD137, Security (finance), BTC, Private Securities Litigation Reform Act, Treatment, Cancer research, MT1-MMP, Journal, Clinical trial, Forward-looking statement, Medicinal chemistry, Thromboxane A2, Journal of Medicinal Chemistry, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in the Journal of Medicinal Chemistry.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in the Journal of Medicinal Chemistry.
  • The article, titled Discovery of BT8009: a Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer is available at the publications section of the Bicycle website at this link .
  • The pre-clinical data published in the Journal of Medicinal Chemistry describe the discovery of our clinical-stage Bicycle Toxin Conjugate candidate targeting Nectin-4 expressing tumors, said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

LifeMine Therapeutics Expands Management Team with Appointments of Martin Stahl, Ph.D., as Chief Scientific Officer and Louis Plamondon, Ph.D., as Executive Vice President and Head of CMC

Retrieved on: 
Thursday, October 6, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Constellation, Philippe Ciais, Gemstone, Doctor of Philosophy, Therapy, Computer, Head, Cambridge Crystallographic Data Centre, ChemMedChem, Cell engineering, Multiple myeloma, Bortezomib, Patient, Pharmacy, CMC, Computational chemistry, Drug discovery, Multiplicity of infection, Negotiation, Harvard University, Journal, University of Freiburg, Medicinal chemistry, University, Biophysics, Journal of Medicinal Chemistry, Data science, Biochemistry, Fine chemical, Pharmaceutical industry, MorphoSys, Chemistry

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.

Key Points: 
  • LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointments of Martin Stahl, Ph.D., as chief scientific officer and Louis Plamondon, Ph.D., as executive vice president and head of CMC.
  • Dr. Stahl, former global head of lead discovery at Roche, will also lead LifeMines operations at its European offices in Basel, Switzerland.
  • Martin and Louis are stellar additions to the LifeMine executive team and share in our vision to reinvent small molecule drug discovery through genomic search and retrieval from the biosphere, said Gregory Verdine, Ph.D., co-founder, president and chief executive officer of LifeMine.
  • Martin and Louis experience and expertise will only help further accelerate our efforts.

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry

Retrieved on: 
Tuesday, July 12, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Technology, SEC, Clinical trial, Medicinal chemistry, Security (finance), Drug development, Biotechnology, U.S. Securities and Exchange Commission, Bicycle, Therapy, Thromboxane A2, BTC, Risk, Journal of Medicinal Chemistry, Journal, Cancer research, COVID-19, Private Securities Litigation Reform Act, Solubility, MT1-MMP, CD137, Forward-looking statement, NASDAQ, Fine chemical, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT7480, a Bicycle tumor-targeted immune cell agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal of Medicinal Chemistry.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT7480, a Bicycle tumor-targeted immune cell agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal of Medicinal Chemistry.
  • We discovered BT7480 by using a series of novel Bicycles targeting CD137, which were conjugated to novel Bicycles targeting Nectin-4, said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts.

Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

Retrieved on: 
Wednesday, November 10, 2021
Journal of Medicinal Chemistry, Osteosarcoma, Safety, CTA, Private Securities Litigation Reform Act, European Society for Medical Oncology, SAN, U.S. Securities and Exchange Commission, EST, Congress, Medicinal chemistry, Failure, Food, Administration, COVID-19, EGFR, ESMO, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Public expenditure, Woman, Company, GLOBE, Development, ...Continued, Therapy, SERD, NSCLC, SEC, Journal, Large-cell lung carcinoma, Review, Oncology, Patient, FDA, WEE1, Cryptocurrency, Pharmaceutical industry

NEW YORK and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate accomplishments.

Key Points: 
  • In August 2021, Zentera, a Shanghai-based clinical-stage biopharmaceutical company formed by Zentalis, announced the completion of a $75 million Series B financing.
  • In July 2021, Zentalis closed an underwritten follow-on offering of 3,565,000 shares of its common stock at a public offering price of $48.50 per share.
  • Cash and Marketable Securities Position:As of September 30, 2021, Zentalis had cash, cash equivalents and marketable securities of $366.8 million.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief Scientific Officer

Retrieved on: 
Tuesday, October 26, 2021
PNAS, Method, Engineering, Biology, Neurology, Amgen, Industry, Medicinal chemistry, Journal of Medicinal Chemistry, CNS, Duke University, History, Patient, Drug discovery, Leadership, Company, CEO, UCSF, Lists of diseases, Program, Data science, Nasdaq, Therapy, GLOBE, Central nervous system, Journal, Pharmaceutical industry, Medical device

Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (Vyant Bio, Company) (Nasdaq: VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases, announced today the appointment of Robert T. Fremeau Jr., Ph.D., as Chief Scientific Officer.

Key Points: 
  • Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (Vyant Bio, Company) (Nasdaq: VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases, announced today the appointment of Robert T. Fremeau Jr., Ph.D., as Chief Scientific Officer.
  • We are thrilled to have Dr. Fremeau join the Vyant Bio team, said Jay Roberts, President and CEO of Vyant Bio.
  • Vyant Bio, Inc. (Vyant Bio, the Company) (Nasdaq: VYNT) has developed a drug discovery engine centered on revolutionary human-derived biology that incorporates advanced technology driven chemistry, data science, and engineering with global regulatory expertise.
  • Vyant Bio is headquartered in the US, with offices in Europe, and research facilities in Australia.

Delix Therapeutics Announces Appointment of Dr. John Krystal to Scientific & Strategic Advisory Board

Retrieved on: 
Monday, October 25, 2021
Science, Depression, Post-traumatic stress disorder, Research, Medicinal chemistry, National academy, MDMA, Yale University, Journal of Medicinal Chemistry, Patient, FDA, U.S. Department of Defense Strategy for Operating in Cyberspace, National Center for Telehealth & Technology, Translational research, Psilocybin, PTSD, Lists of diseases, Ketamine, Leadership, Brain, Company, Mental health, National Academy of Medicine, Translational neuroscience, Awareness, Biological Psychiatry (journal), Molecular Psychiatry, Schizophrenia, Therapy, Publication, Yale New Haven Hospital, Yale Center for Environmental Law & Policy, NASEM, Doctor of Philosophy, Department, U.S. Department of Veterans Affairs, Office of Inspector General, NIAAA, Frontiers, Journal, Pharmaceutical industry

Delix's Scientific and Strategic Advisory Board is comprised of leaders with decades of research and commercial experience to help Delix advance its platform of novel non-hallucinogenic psychedelic-inspired analogs intoorally-bioavailable, take-home therapies.

Key Points: 
  • Delix's Scientific and Strategic Advisory Board is comprised of leaders with decades of research and commercial experience to help Delix advance its platform of novel non-hallucinogenic psychedelic-inspired analogs intoorally-bioavailable, take-home therapies.
  • Delix's scientific approach for developing scalable treatments for brain disorders was recently featured in the scientific journal Frontiers in Psychiatry .
  • Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogensnovel neuroplasticity-promoting therapeuticsto better treat mental health disorders at scale.
  • Delix is rapidly advancing these compounds through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs.

MPM Strengthens its Team with the Addition of Accomplished Biotech Executive and Drug Discoverer Wendy Young, PhD

Retrieved on: 
Thursday, September 23, 2021
Other Professional Services, Biotechnology, Finance, Health, Consulting, Banking, Professional Services, Other Health, Molecule, Biotechnology, MPM, ACS, Medicinal chemistry, Eli Lilly, Woman, Celera Corporation, Patient, Chemistry, Genentech, Lung cancer, Princeton University, Leadership, Medicine, Journal of Medicinal Chemistry, Science, Technology, Journal, Research, Drug development, Drug discovery, R, Laboratory, Doctor of Philosophy, SVP, Multiple sclerosis, Breast cancer, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry

MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive and drug discoverer Wendy Young, PhD, to its team of accomplished Executive Partners.

Key Points: 
  • MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive and drug discoverer Wendy Young, PhD, to its team of accomplished Executive Partners.
  • At Genentech, Wendy led research activities and oversaw 900 internal and external multi-disciplinary scientists engaged in drug discovery.
  • Earlier in her career, Wendy held drug discovery roles at SCIOS, a Johnson & Johnson Company, and Celera Genomics.
  • Were delighted that Wendy has joined our senior team of MPM Entrepreneurs, said Ed Hurwitz, Managing Director, MPM Capital.

Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3

Retrieved on: 
Wednesday, September 1, 2021
Cell death, Cancer, Company, Journal, Private Securities Litigation Reform Act, SERD, Therapy, U.S. Securities and Exchange Commission, EGFR, GLOBE, SEC, Research, DNA, Medicinal chemistry, DNA repair, Safety, WEE1, Patient, NSCLC, SAN, Osteosarcoma, Large-cell lung carcinoma, Cell cycle, FDA, Journal of Medicinal Chemistry, Pharmaceutical industry

The inhibition of WEE1, a key regulator of the cell cycle, is a clinically validated approach for cancer treatment.

Key Points: 
  • The inhibition of WEE1, a key regulator of the cell cycle, is a clinically validated approach for cancer treatment.
  • The paper reviews Zentalis objectives in designing ZN-c3 as a potentially safer and more selective WEE1 inhibitor, overcoming limitations seen with other WEE1 inhibitors.
  • In addition, Zentalis has identified potential accelerated approval paths for ZN-c3 in both uterine serous carcinoma and a biomarker-driven setting.
  • ZN-c3 is a potentially first-in-class and best-in-class oral inhibitor of WEE1 in development for the treatment of advanced solid tumors.